SCHEMBL7149243

SCHEMBL7149243

COc1ccc2nc(SCCCCS(=O)(=O)Nc3ccccc3OC)sc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
NFKB1 P19838 1/20 0.51
GFER P55789 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
LMNA P02545 3/20 0.48
MAPK1 P28482 2/20 0.48
HTT P42858 1/20 0.48
PDK1 Q15118 1/20 0.46
CSNK1D P48730 1/20 0.43
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 1/20 0.41
CTSL P07711 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7151765 0.97 MAPT (0.52) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL7149130 0.93 MAPT (0.53) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL7151731 0.91 MAPT (0.48) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL7149211 0.89 ALDH1A1 (0.53) MAPTKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL7152196 0.88 MAPT (0.49) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL7153200 0.88 MAPT (0.55) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL7152202 0.87 MAPT (0.49) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL7148781 0.86 ALDH1A1 (0.54) MAPTKMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL7146179 0.85 PDK1 (0.50) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL7146609 0.85 MAPT (0.42) MAPTMEN1KMT2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 MAPT 3839/4885MEN1 4162/4885KMT2A 4174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.